Yumi Itoh
Osaka, 5650871, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Evolutionary dynamics of heparan sulfate utilization by SARS-CoV-2.
Journal: mBio
Published: June 23, 2025
Engineered ACE2 decoy in dry powder form for inhalation: A novel therapy for SARS-CoV-2 variants.
Journal: Molecular therapy. Methods & clinical development
Published: November 12, 2024
In vivo production of engineered ACE2 decoy protects lungs from SARS-CoV-2 infection.
Journal: Molecular therapy. Nucleic acids
Published: October 15, 2024
Selective TLR ligand stimulation enhances in vivo mosquito-borne flavivirus pathogenicity.
Journal: Cell reports
Published: October 10, 2024
An inhaled ACE2 decoy confers protection against SARS-CoV-2 infection in preclinical models.
Journal: Science translational medicine
Published: August 30, 2023
Nsp14 of SARS-CoV-2 inhibits mRNA processing and nuclear export by targeting the nuclear cap-binding complex.
Journal: Nucleic acids research
Published: February 15, 2023
A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo.
Journal: Communications biology
Published: January 12, 2023
Development of an engineered ACE2 decoy for COVID-19 therapy.
Journal: Uirusu
Published: January 01, 2023
Antibody feedback contributes to facilitating the development of Omicron-reactive memory B cells in SARS-CoV-2 mRNA vaccinees.
Journal: The Journal of experimental medicine
Published: October 19, 2022
An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo.
Journal: Science translational medicine
Published: April 26, 2022
Engineered ACE2 receptor has a potential for a new therapy of COVID-19
Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica
Published: March 01, 2022
Last Updated: 09/26/2026